Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 51013

Next Previous
X
Search
Drug Profile

BI 51013

Alternative Names: Anti-alpha-beta-TCR monoclonal antibody BMA-031; Anti-T cell receptor alphabeta monoclonal antibody BMA031; Anti-TCR-alphabeta monoclonal antibody BMA031; Behring Monoclonal Antibody; BMA 031; Monoclonal antibody BMA031

Latest Information Update: 26 Jan 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aventis Behring LLC
  • Developer Aventis Behring
  • Class Monoclonal antibodies
  • Mechanism of Action T-cell receptor antigen alpha-beta antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Graft-versus-host disease; Renal transplant rejection; Transplant rejection

Most Recent Events

  • 25 Jan 2017 Discontinued - Phase-II for Graft-versus-host disease in Germany, USA (unspecified route)
  • 25 Jan 2017 Discontinued - Phase-III for Renal transplant rejection in USA, Germany (IV)
  • 25 Jan 2017 Discontinued - Preclinical for Transplant rejection in Japan (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top